+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Certolizumab Pegol"

TNF Alpha Inhibitors Global Market Report 2024 - Product Thumbnail Image

TNF Alpha Inhibitors Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024 - Product Thumbnail Image

Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

  • Report
  • March 2018
  • 300 Pages
  • Global
From
Antibody Fragments Market Size, Share & Trends Analysis Report by Specificity (Monoclonal Antibodies, Polyclonal Antibodies), by Type, by Therapy, by Application, by Region, and Segment Forecasts, 2022-2030 - Product Thumbnail Image

Antibody Fragments Market Size, Share & Trends Analysis Report by Specificity (Monoclonal Antibodies, Polyclonal Antibodies), by Type, by Therapy, by Application, by Region, and Segment Forecasts, 2022-2030

  • Report
  • August 2022
  • 150 Pages
  • Global
From
TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions - Global Forecast up to 2025 - Product Thumbnail Image

TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions - Global Forecast up to 2025

  • Report
  • August 2019
  • 140 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Certolizumab Pegol is a biologic drug used in the treatment of oncology. It is a humanized monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), a cytokine involved in inflammation and cancer progression. Certolizumab Pegol is used to treat a variety of cancers, including colorectal, breast, and lung cancer. It is also used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. Certolizumab Pegol is administered intravenously or subcutaneously, and is available in both brand-name and generic formulations. Certolizumab Pegol is a relatively new drug, and is still in the early stages of development. It is currently approved for use in the United States, Europe, and other countries. Clinical trials are ongoing to evaluate its efficacy in other types of cancer and autoimmune diseases. Companies in the Certolizumab Pegol market include UCB, Pfizer, Merck, and AbbVie. Show Less Read more